← All trials
NCT05709548
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 15, 2023
- Primary completion
- Dec 31, 2025
- Completion date
- Dec 31, 2025
- First posted
- Feb 2, 2023
- Last posted
- Sep 29, 2023
- Enrollment
- 440
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Corporacion Parc TauliLead sponsor
- Corporacion Parc TauliOverall official - principal investigator
- Corporacion Parc TauliReponsible party - principal investigator
- Badalona Hospital Germans Trias i PujolOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.